Zacks: Analysts Anticipate Minerva Neurosciences, Inc. (NASDAQ:NERV) to Post -$0.16 Earnings Per Share

Wall Street brokerages expect Minerva Neurosciences, Inc. (NASDAQ:NERVGet Rating) to announce earnings per share of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Minerva Neurosciences’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.18). Minerva Neurosciences posted earnings per share of ($0.25) during the same quarter last year, which would suggest a positive year over year growth rate of 36%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.82) to ($0.57). For the next year, analysts expect that the business will post earnings of ($0.61) per share, with EPS estimates ranging from ($0.70) to ($0.51). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERVGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.05).

NERV has been the subject of several recent analyst reports. StockNews.com assumed coverage on Minerva Neurosciences in a report on Thursday. They issued a “sell” rating for the company. Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday. Finally, HC Wainwright lowered their price objective on Minerva Neurosciences to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 4th.

NASDAQ NERV opened at $0.47 on Friday. The firm has a market cap of $20.08 million, a P/E ratio of -0.39 and a beta of 1.13. Minerva Neurosciences has a 12 month low of $0.47 and a 12 month high of $3.54. The firm has a 50 day moving average of $0.71.

Several hedge funds have recently made changes to their positions in NERV. GSA Capital Partners LLP boosted its stake in shares of Minerva Neurosciences by 26.0% during the third quarter. GSA Capital Partners LLP now owns 480,629 shares of the biopharmaceutical company’s stock valued at $836,000 after purchasing an additional 99,141 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Minerva Neurosciences by 20.2% in the third quarter. BlackRock Inc. now owns 488,370 shares of the biopharmaceutical company’s stock worth $850,000 after acquiring an additional 81,904 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Minerva Neurosciences by 3.4% in the fourth quarter. Acadian Asset Management LLC now owns 1,768,685 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 58,202 shares during the period. Rafferty Asset Management LLC acquired a new position in shares of Minerva Neurosciences in the third quarter worth approximately $85,000. Finally, Geode Capital Management LLC lifted its stake in shares of Minerva Neurosciences by 9.7% in the third quarter. Geode Capital Management LLC now owns 488,813 shares of the biopharmaceutical company’s stock worth $850,000 after acquiring an additional 43,034 shares during the period. 48.59% of the stock is currently owned by hedge funds and other institutional investors.

About Minerva Neurosciences (Get Rating)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Further Reading

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.